IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
Gastroenterology Unit, A.O. Ordine Mauriziano, Turin, Italy.
Dig Liver Dis. 2019 Jul;51(7):972-977. doi: 10.1016/j.dld.2019.03.007. Epub 2019 Apr 13.
Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis.
to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription.
This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD.
Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event.
Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.
关于同时患有银屑病或银屑病关节炎的炎症性肠病（IBD）患者接受乌司奴单抗治疗的效果，目前相关数据有限。
描述通过皮肤科或风湿科处方接受乌司奴单抗治疗的 IBD 患者的结局。
这是一项多中心、回顾性研究，纳入了所有因同时患有活动性银屑病/银屑病关节炎而开始接受乌司奴单抗治疗的 IBD 患者，无论 IBD 活动度如何。主要终点是乌司奴单抗的总体维持率，定义为因 IBD 的持续临床获益而维持治疗。
共纳入 70 例患者（64 例克罗恩病/6 例溃疡性结肠炎）。乌司奴单抗治疗的中位随访时间为 10.7 个月（范围 1.4-67.3）。12 例患者（17.1%）在中位 7.4 个月（范围 0.9-23.8）后停药。6 个月时维持乌司奴单抗治疗的累积概率为 97.1%，12 个月时为 77.1%。在基线时患有活动性 IBD 的 56 例患者中，34 例（60.7%）在最后一次随访时达到临床缓解。他们达到临床缓解的累积概率分别为 84.7%和 63.9%，分别在 6 个月和 12 个月时。有 2 例患者因不良事件停止使用乌司奴单抗。
对于同时患有皮肤病或风湿病的 IBD 患者，皮下注射乌司奴单抗具有良好的疗效。
